Cargando…

Antibody response to the messenger RNA‐1273 vaccine (Moderna) in liver transplant recipients

Different reports have shown the clinical and serologic response to the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) messenger RNA (mRNA) vaccines in preventing coronavirus disease 2019 (COVID‐19) in the general population, but few studies have examined these responses in transplant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuadrado, Antonio, del Barrio, María, Fortea, José Ignacio, Amigo, Lidia, San Segundo, David, Rodriguez‐Cundin, María Paz, Rebollo, María Henar, Fernandez‐Santiago, Roberto, Castillo, Federico, Achalandabaso, Maria, Echeverri, Juan, Anderson, Edward J., Rodríguez‐Sanjuan, Juan Carlos, López‐Hoyos, Marcos, Crespo, Javier, Fábrega, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110949/ https://www.ncbi.nlm.nih.gov/pubmed/35344281 http://dx.doi.org/10.1002/hep4.1937

Ejemplares similares

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients
por: Herrán, Aitor Odriozola, et al.
Publicado: (2022)

Hypersensitivity reactions following the Moderna messenger RNA-1273 vaccine
por: Drohan, Alex, et al.
Publicado: (2021)

Risk of Recurrence of Hepatocarcinoma after Liver Transplantation: Performance of Recurrence Predictive Models in a Cohort of Transplant Patients
por: Cuadrado, Antonio, et al.
Publicado: (2023)

Multiple Keratoacanthomas Following Moderna Messenger RNA-1273 COVID-19 Vaccination Resolved With 5-Fluorouracil Treatment: Case Report
por: Ahmed, Fahad, et al.
Publicado: (2022)

Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
por: Desai, Amar D, et al.
Publicado: (2022)

Acquired Angioedema Acute Attack After Administration of the Moderna COVID-19 (mRNA-1273) Vaccine
por: Graziani, Alessandro, et al.
Publicado: (2023)

De novo vasculitis after mRNA-1273 (Moderna) vaccination
por: Anderegg, Manuel A., et al.
Publicado: (2021)

Pityriasis rubra pilaris potentially triggered by messenger RNA–1273 COVID vaccine
por: Ajebo, Etsubdenk M., et al.
Publicado: (2022)

Central retinal artery occlusion after Moderna mRNA-1273 vaccination
por: Chow, Sin Yu, et al.
Publicado: (2022)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination: Author's response
por: Pereson, Matías J., et al.
Publicado: (2022)

Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine
por: Malayala, Srikrishna V, et al.
Publicado: (2021)

New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
por: Kaminetsky, Joshua, et al.
Publicado: (2021)

Pityriasis rosea after Moderna mRNA‐1273 vaccine: A case series
por: Martora, Fabrizio, et al.
Publicado: (2021)

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
por: Scoccianti, Silvia, et al.
Publicado: (2021)

Is Routine Prophylaxis Against Pneumocystis jirovecii Needed in Liver Transplantation? A Retrospective Single-Centre Experience and Current Prophylaxis Strategies in Spain
por: Fortea, José Ignacio, et al.
Publicado: (2020)

Study of humoral and cellular immunity in vaccinated with mRNA‐1273
por: Gutiérrez‐Bautista, Juan Francisco, et al.
Publicado: (2022)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Re: Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial
por: Cuadrado-Lavín, Antonio, et al.
Publicado: (2020)

Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
por: Channa, Leelakrishna, et al.
Publicado: (2021)

Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine
por: Holzworth, Amy, et al.
Publicado: (2021)

Bell's palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19
por: Poudel, Sujan, et al.
Publicado: (2022)

2336. General Safety Profile of mRNA-1273 (Moderna COVID-19 Vaccine) in the Elderly Population
por: Anteyi, Kate, et al.
Publicado: (2023)

Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine
por: Agaronov, Anna, et al.
Publicado: (2021)

The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease
por: Arias-Loste, María Teresa, et al.
Publicado: (2015)

Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases
por: De Santis, Maria, et al.
Publicado: (2022)

Guillain‐Barré syndrome after mRNA‐1273 (Moderna) COVID‐19 vaccination: A case report
por: Anjum, Zauraiz, et al.
Publicado: (2022)

Paucisymptomatic COVID-19 in lung transplant recipient following two doses of mRNA-1273 (Moderna) vaccine
por: Marinelli, Tina, et al.
Publicado: (2021)

Cutaneous Sarcoidosis-like Eruption Following Second Dose of Moderna mRNA-1273 Vaccine: Case or Relationship?
por: Cazzato, Gerardo, et al.
Publicado: (2023)

2357. Descriptive Analyses of mRNA-1273 (Moderna COVID-19 vaccine) Spontaneous Reports by Geographic Regions
por: Emile-Backer, Magalie, et al.
Publicado: (2023)

Livedo reticularis on bilateral knees after the third dose of messenger RNA-1273 SARS-CoV-2 vaccine
por: Mintz, Michelle Amy, et al.
Publicado: (2022)

Periprocedural management of hemostatic alterations in patients with cirrhosis and vascular liver disorders: a step forward of the American Association for the Study of Liver Diseases
por: Fortea, José Ignacio, et al.
Publicado: (2023)

Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
por: Kong, Joyce, et al.
Publicado: (2021)

De-novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19
por: Feghali, Elio Junior, et al.
Publicado: (2021)

Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report
por: Iwata, Masahiro, et al.
Publicado: (2022)

Extracellular Vesicles and Cancer Multidrug Resistance: Undesirable Intercellular Messengers?
por: Bucci-Muñoz, María, et al.
Publicado: (2023)

Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients
por: Kaiser, Robert A., et al.
Publicado: (2021)

Case Report: Vaccine-Induced Immune Thrombotic Thrombocytopenia in a Pancreatic Cancer Patient After Vaccination With Messenger RNA−1273
por: Su, Po-Hsu, et al.
Publicado: (2021)

Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk
por: Golan, Yarden, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r5bj5vbt0jvh7fdab04bl80vsq